TriSalus Life Sciences (TLSI) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
TriSalus Life Sciences insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $3.6M and 5 sold $140K of TLSI stock on the open market, including a cluster buy that began May 15, 2026.
Get emailed when insiders cluster-buy stocks like TLSI
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
TLSI insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $4K | 3 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | $1.8M | 6 | $1K | 1 |
| Q1 2026 | $1.8M | 6 | $134K | 14 |
Valuation, profit and volume
Summary
Over the past 12 months, 6 TriSalus Life Sciences, Inc. insiders reported open-market purchases totaling $3.6M, while 5 insiders reported sales totaling $140K. The most recent cluster buy began on May 15, 2026, when 5 insiders bought a combined $1.8M. Among insiders with enough purchase history to measure, Michael P Stansky (Director) has the highest Insider Score at 68. 0 of 18 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 7SEC | Richard MarshakChief Commercial Officer | Sell | 325127,994 held (−0%) | $4.39 | $1K | -7.5% | — |
| Oct 7SEC | Jennifer StevensChief Regulatory Officer | Sell | 316123,794 held (−0%) | $4.39 | $1K | -7.5% | — |
| Oct 7SEC | Bryan F. CoxChief Of Research | Sell | 296162,805 held (−0%) | $4.39 | $1K | -7.5% | — |
| May 19SEC | Richard MarshakChief Commercial Officer | Sell | 543125,101 held (−0%) | $2.67 | $1K | +52.1% | — |
| May 18SEC | Michael P StanskyDirector | Buy | 410,0001,240,722 held (+49%) | $2.50 | $1.0M | +62.4% | 68 |
| May 18SEC | Michael P StanskyDirector | Buy | 200,000399,698 held (+100%) | $2.50 | $500K | +62.4% | 68 |
| May 18SEC | Mats WahlstromDirector | Buy | 60,000147,555 held (+69%) | $2.53 | $152K | +60.5% | — |
| May 18SEC | Mary T SzelaCEO, President | Buy | 39,6821,065,215 held (+4%) | $2.59 | $103K | +56.8% | 63 |
| May 18SEC | Gary B. GordonDirector | Buy | 10,00072,510 held (+16%) | $2.46 | $25K | +65.0% | 68 |
| May 18SEC | David PatienceCFO | Buy | 7,100275,757 held (+3%) | $2.43 | $17K | +67.1% | 68 |
| Mar 20SEC | Mary T SzelaCEO, President | Sell | 15,944752,987 held (−2%) | $3.85 | $61K | +5.5% | 63 |
| Mar 20SEC | Mary T SzelaCEO, President | Sell | 4,358768,931 held (−1%) | $4.13 | $18K | -1.7% | 63 |
| Mar 20SEC | Jodi DevlinChief Of Clinical Operations | Sell | 1,77297,637 held (−2%) | $4.09 | $7K | -0.7% | — |
| Mar 20SEC | Richard MarshakChief Commercial Officer | Sell | 1,589110,816 held (−1%) | $4.09 | $6K | -0.7% | — |
| Mar 20SEC | Jennifer StevensChief Regulatory Officer | Sell | 1,552124,884 held (−1%) | $4.09 | $6K | -0.7% | — |
| Mar 20SEC | Bryan F. CoxChief Of Research | Sell | 1,467163,994 held (−1%) | $4.09 | $6K | -0.7% | — |
| Mar 20SEC | Richard MarshakChief Commercial Officer | Sell | 1,449112,405 held (−1%) | $4.13 | $6K | -1.7% | — |
| Mar 20SEC | Jennifer StevensChief Regulatory Officer | Sell | 1,204126,436 held (−1%) | $4.13 | $5K | -1.7% | — |
| Mar 20SEC | Jodi DevlinChief Of Clinical Operations | Sell | 1,16299,409 held (−1%) | $4.13 | $5K | -1.7% | — |
| Mar 20SEC | Bryan F. CoxChief Of Research | Sell | 1,138165,461 held (−1%) | $4.13 | $5K | -1.7% | — |
| Mar 20SEC | Jennifer StevensChief Regulatory Officer | Sell | 774124,110 held (−1%) | $4.12 | $3K | -1.5% | — |
| Mar 20SEC | Bryan F. CoxChief Of Research | Sell | 579163,415 held (−0%) | $4.12 | $2K | -1.5% | — |
| Mar 20SEC | Richard MarshakChief Commercial Officer | Sell | 419110,397 held (−0%) | $4.12 | $2K | -1.5% | — |
| Mar 20SEC | Jodi DevlinChief Of Clinical Operations | Sell | 27397,364 held (−0%) | $4.12 | $1K | -1.5% | — |
| Feb 23SEC | Michael P StanskyDirector | Buy | 243,900787,132 held (+45%) | $4.10 | $1000K | -1.0% | 68 |
| Feb 23SEC | Michael P StanskyDirector | Buy | 117,198199,698 held (+142%) | $4.10 | $481K | -1.0% | 68 |
| Feb 23SEC | Mary T SzelaCEO, President | Buy | 30,487773,289 held (+4%) | $4.10 | $125K | -1.0% | 63 |
| Feb 23SEC | William ValleDirector | Buy | 30,487new position | $4.10 | $125K | -1.0% | — |
| Feb 23SEC | Gary B. GordonDirector | Buy | 9,756new position | $4.10 | $40K | -1.0% | 68 |
| Feb 23SEC | David PatienceCFO | Buy | 3,657268,657 held (+1%) | $4.10 | $15K | -1.0% | 68 |
Insiders at TriSalus Life Sciences, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Michael P StanskyDirector | $3.0M | — | May 18, 2026 | 68 |
| Mary T SzelaCEO, President | $228K | $79K | May 18, 2026 | 63 |
| Mats WahlstromDirector | $152K | — | May 18, 2026 | — |
| William ValleDirector | $125K | — | Feb 23, 2026 | — |
| Gary B. GordonDirector | $65K | — | May 18, 2026 | 68 |
| David PatienceCFO | $32K | — | May 18, 2026 | 68 |
| Richard MarshakChief Commercial Officer | — | $17K | Oct 7, 2026 | — |
| Jennifer StevensChief Regulatory Officer | — | $16K | Oct 7, 2026 | — |
| Bryan F. CoxChief Of Research | — | $14K | Oct 7, 2026 | — |
| Jodi DevlinChief Of Clinical Operations | — | $13K | Mar 20, 2026 | — |
TLSI stock: common questions
Are TriSalus Life Sciences, Inc. insiders buying TLSI stock?
In the past 12 months, 6 insiders reported open-market purchases of TLSI worth $3.6M. The latest was Director Michael P Stansky bought $1.0M of TLSI at $2.50 — raises the stake by 49%.
Are TriSalus Life Sciences, Inc. insiders selling TLSI stock?
5 insiders reported sales worth $140K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is TLSI's 52-week range?
Over the past year TLSI has traded between $2.52 and $7.50. It last closed at $4.06 on Oct 9, 2026.